- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Topical Ivermectin Effective for Mild to Moderate Inflamed Rhinophyma, Study Finds
Italy: A recent randomized controlled study has highlighted the effectiveness of topical ivermectin in treating inflamed rhinophyma, a severe form of rosacea characterized by facial inflammation and thickening. The study, which focused on using 1% ivermectin (IVM) cream applied twice daily, found that this treatment significantly improved patient outcomes. Approximately 60% of participants with mild to moderate inflamed rhinophyma achieved a status of clear or almost clear skin, showcasing ivermectin's potential as a viable therapeutic option.
"Applying 1% ivermectin cream twice daily seems to be an effective treatment for patients with mild to moderate inflamed rhinophyma, with 60% of patients achieving clear or nearly clear skin," the researchers wrote in their study published in the Journal of the American Academy of Dermatology.
According to the ROSacea COnsensus panel, inflamed rhinophyma is a distinct rosacea marked by erythema, prominent dilated pilosebaceous pores, and recurrent papules or pustules. Managing this condition remains difficult due to the lack of a specific approved drug for treatment. Giuseppe Micali, University of Catania, Catania, Italy, and colleagues aimed to assess the efficacy and tolerability of ivermectin 1% cream applied once or twice daily compared to metronidazole (MTZ) 0.75% gel used twice daily—both treatments approved for inflammatory rosacea—a 12-week evaluation was conducted in patients with mild to moderate inflamed rhinophyma.
For this purpose, the researchers conducted a randomized controlled trial with 50 new adult patients (40 males, 10 females; mean age 62.7 years) suffering from mild to moderate nasal rhinophyma, characterized by erythema and papules/pustules. Participants were randomly assigned to receive either IVM 1% cream once daily (20 patients), IVM 1% cream twice daily (20 patients), or MTZ 0.75% gel twice daily (10 patients) in a 1:1:1 ratio.
To minimize bias, a blinded investigator-assessed all patients at baseline, eight weeks, and 12 weeks. Clinical evaluations included erythema severity and overall efficacy, while instrumental assessments were conducted using erythema-directed digital photography. Tolerability and cosmetic acceptability were measured with a self-administered questionnaire. Data were analyzed using SPSS software, and patients with clear or nearly clear responses had a follow-up visit at eight weeks.
The following were the revelations of the study:
- At week 8, a statistically superior success profile from the baseline of Investigator Erythema Severity Assessment (from mean 2 ± 0.64 to 1.45 ± 0.75) and erythema-directed digital photography scores (from mean 2.35 ± 0.58 to 1.5 ± 0.82) was observed with IVM twice daily compared with both IVM once daily and MTZ twice daily.
- At week 12, additional significant clinical (Investigator Erythema Severity Assessment: mean from 2 ± 0.64 to 1.1 ± 0.64) and instrumental (erythema-directed digital photography: mean from 2.35 ± 0.58 to 1.5 ± 0.82) improvement was seen.
- These results were consistent with those from Investigator Global Assessment, which showed, for IVM once or twice daily or MTZ twice daily: clear in 10% versus 25% versus 20% and almost clear in 25% versus 35% versus 0% of patients, respectively.
- All regimens were safe and well tolerated, and no dropouts were observed.
- Follow-up showed that patients treated with IVM twice daily were able to maintain the results for a longer time (36 days) compared with those treated with IVM once daily (25 days) and MTZ twice daily (18 days).
Despite these promising results, the study acknowledges several limitations. Conducted as an open-label, single-center trial without a placebo group, it involved a relatively small patient cohort.
"As a result, while the findings are encouraging, further research involving larger, placebo-controlled trials is necessary to validate these results and assess the broader applicability of ivermectin for rhinophyma treatment," the researchers concluded.
Reference:
Dall'Oglio F, Nasca MR, Vitale P, Platania H, Micali G. Inflamed rhinophyma treated with topical ivermectin: A randomized controlled study. J Am Acad Dermatol. 2024 Sep;91(3):519-521. doi: 10.1016/j.jaad.2024.03.051. Epub 2024 Apr 30. PMID: 38697218.
MSc. Biotechnology
Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at  editorial@medicaldialogues.in. Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751